Paul Biondi
Senior Vice President, R&D Operations @ Bristol-Myers Squibb
New York, United States
Paul Biondi is a Series B investor at Bristol-Myers Squibb in New York focused on Medical and Genetics. Paul Biondi is the executive partner at Flagship Pioneering.Paul Biondi attended Northwestern University - Kellogg School of Management.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Paul Biondi invests in
Stages Paul Biondi invests in
Countries Paul Biondi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (100%)
- Genetics 1 (100%)
- Analytics 1 (100%)
- Biotechnology 1 (100%)
- Bioinformatics 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basisof human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States. | $75M / Series B / Jan 04, 2018 |
Co-Investors
3B Future Health Fund
1 deal together
Inova Strategic Investments
1 deal together
Maryland Venture Fund
1 deal together
New Enterprise Associates
1 deal together
Windham Venture Partners
1 deal together
About Bristol-Myers Squibb
Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products.
Bristol-Myers Squibb Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John damonti
Foundation President
|
|||
Chris Boerner
Executive Vice President, Chief Commercialization Officer
|
|||
Debra Boyko-DeBrito
Director Content Management Solutions
|
|||
Donald J. Hayden, Jr.
President
|
|||
Doug Bassett
SVP Informatics & Predictive Sciences
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Paul Biondi invest in?
Paul Biondi invests primarily in Medical, Genetics and Analytics startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Paul Biondi?
Public channels for Paul Biondi include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Paul Biondi last invest?
The most recent investment recorded for Paul Biondi closed in Jan 2018. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
